Citalopram Tablet
Product Images NDC 50090-5175

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Citalopram (NDC 50090-5175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 01)

Chemical structure diagram of Citalopram hydrobromide showing its molecular arrangement with labeled functional groups and bonds.*

FDA Label Image

Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 02)

A data table titled 'Table 1' showing the drug-placebo difference in number of cases of suicidality per 1000 patients treated with Citalopram. It lists age ranges (<18, 18-24, 25-64, ≥65) and corresponding suicidality case changes compared to placebo, indicating increases for ages under 25 and decreases for ages 25 and above.*

FDA Label Image

Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 03)

Table showing treatment-emergent adverse events incidence in placebo-controlled clinical trials comparing Citalopram (N=1063) and placebo (N=446). It lists percentages of patients reporting events across various body systems, including autonomic nervous, central and peripheral nervous, gastrointestinal, general, musculoskeletal, psychiatric, respiratory, and urogenital disorders, with higher rates generally seen in Citalopram-treated patients.*

FDA Label Image

Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 04)

A data table titled 'Adverse Events Associated With Discontinuation of Treatment in Short-Term, Placebo-Controlled, Depression Trials.' The table compares the percentage of patients discontinuing treatment due to adverse events for Citalopram and placebo. It lists body systems and specific adverse events such as asthenia, nausea, dry mouth, vomiting, dizziness, insomnia, somnolence, and agitation with corresponding discontinuation percentages for each group.*

FDA Label Image

Label Image (Lbl500905175)

Citalopram 40 mg oral tablets by A-S Medication Solutions. The label shows the product number 5627-1 and specifies each tablet contains citalopram hydrobromide equivalent to 40 mg of citalopram. The package contains 100 tablets. Storage instructions indicate to store at 68 to 77 degrees Fahrenheit. Manufacturer is Invagen Pharma, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.